Trials / Completed
CompletedNCT00005629
Vaccine Therapy in Treating Patients With Liver Cancer
Phase I/II Trial Testing Alpha Fetoprotein (AFP) Peptide Immunization in Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Jonsson Comprehensive Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have liver cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AFP gene hepatocellular carcinoma vaccine | Patients will receive three biweekly intradermal vaccinations with four HLA-A\*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51. Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug |
Timeline
- Start date
- 1999-07-01
- Primary completion
- 2002-05-01
- Completion
- 2002-06-01
- First posted
- 2003-10-01
- Last updated
- 2020-08-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00005629. Inclusion in this directory is not an endorsement.